Hua Medicine PT receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease. Hua Medicine (Shanghai) Ltd. was incorporated in 2011 and is based in Shanghai, China.
Metrics to compare | 2552 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2552PeersSector | |
---|---|---|---|---|
P/E Ratio | −11.3x | −16.8x | −0.5x | |
PEG Ratio | 0.63 | 0.04 | 0.00 | |
Price/Book | −20.8x | 3.9x | 2.6x | |
Price / LTM Sales | 11.0x | 5.4x | 3.3x | |
Upside (Analyst Target) | - | −9.3% | 43.3% | |
Fair Value Upside | Unlock | −15.7% | 6.9% | Unlock |